WO2023161921A2

WO2023161921A2 - Compositions for use as an adjunctive therapy in the treatment of breast cancer

Info

Publication number: WO2023161921A2
Application number: PCT/IL2023/050159
Authority: WO
Inventors: Efrat ORON; Basem FARES; Dobroslav Melamed; Itzhak ANGEL; Tamar Peretz
Original assignee: Cannabotech Ltd.
Priority date: 2022-02-23
Filing date: 2023-02-16
Publication date: 2023-08-31
Also published as: WO2023161921A3

Abstract

The present invention relates to particular cannabinoid- and mushroom-based compositions for use as an adjunctive therapy to a conventional therapy for treating a breast cancer.

Description

COMPOSITIONS FOR USE AS AN ADJUNCTIVE THERAPY IN THE TREATMENT OF BREAST CANCER

TECHNICAE FIELD

[0001] The present invention relates to cannabinoid- and mushroom-based compositions for use as an adjunctive therapy to a conventional therapy for treating a breast cancer.

BACKGROUND ART

[0002] There is growing evidence in the literature supporting a role for Cannabis-derived substances in cancer therapy. These substances, collectively referred to as cannabinoids, have varying degrees of biochemical activity, and specifically anticancer activity which makes them effective in a wide spectrum of tumor cells both in vivo and in vitro.

[0003] As previously disclosed, administration of cannabinoids such as A⁸- tetrahydrocannabinol (A⁸-THC), A⁹-tetrahydrocannabinol (A⁹-THC), and cannabidiol (CBD) inhibited the DNA synthesis and growth of lung adenocarcinoma in cultured cells as well as in mouse tumor models. Similar effects were seen in both in vitro and in vivo models of other cancers including glioma, breast, pancreas, prostate, colorectal carcinoma, and lymphoma. There are various proposed mechanisms of action behind these findings, including cell cycle arrest and induction of apoptosis, as well as inhibition of neovascularization, migration, adhesion, invasion, and metastasis.

[0004] Cannabinoids have also been tested in combination with other chemotherapeutic drugs or radiotherapy to establish whether they can enhance the efficacy of conventional treatments. For instance, the administration of CBD together with some anticancer drugs has been shown to increase the susceptibility of glioblastoma cells to the cytotoxic effects of the drugs (Nabissi et al. 2013). It has also been demonstrated that CBD and bortezomib synergistically reduced the viability of transient receptor potential cation channel subfamily V member 2 (TRPV2)-transfected and un-transfected multiple myeloma cell lines. Additionally, it has been shown that mice with pancreatic cancer survived nearly three times longer when their cytostatic treatment was combined with CBD (Zhelyazkova et al., 2020).

[0005] Terpenes are naturally occurring compounds found especially in essential oils, resins, and balsam, which have a broad range of biological properties. For example, terpenes are known as skin penetration enhancers, and were found to have cancer chemo - preventive effects as well as anti-inflammatory activities.

[0006] Medicinal mushrooms have a proven history of use worldwide. Nowadays, medicinal mushrooms are used as dietary food or food supplement products; dietary pet and veterinary food supplements; natural bio-control agents in plant; cosmeceuticals and nutricosmetics; as well as drugs (referred to as “mushroom pharmaceuticals”).

[0007] As particularly disclosed in the art, medicinal mushrooms have shown various medicinal functions including, e.g., antitumor, immunomodulating, antioxidant, radical scavenging, cardiovascular, cholesterol-lowering, antiviral, antibacterial, anti-parasitic, antifungal, detoxification, hepatoprotective, anti-diabetic, anti-obesity, neuroprotective, and neuro-regenerative activities. In addition, substances derived from medicinal mushrooms have been shown as active painkillers or analgesics. The best implementation of medicinal mushroom-based drugs and dietary supplements has been in preventing immune disorders and maintaining a good quality of life, especially in immunodeficient and immuno-depressed patients, patients under chemotherapy or radiotherapy, patients with different types of cancers, chronic blood-borne viral infections of Hepatitis B, C and D, different types of anemia, the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), Herpes simplex virus (HSV), Epstein Bar virus, Influenza viruses A and B, H5N1, COVID-19 (Murphy et al., 2020), West Nile virus, chronic fatigue syndrome, patients with chronic gastritis and gastric ulcers caused by Helicobacter pylori, and people suffering from dementia (especially Alzheimer’s disease) (Wasser, 2010, Chang and Wasser, 2018).

[0008] In many cases, mushrooms were used as adjuvant treatment with conventional chemo- or radiotherapy in different kinds of cancer (Wasser, 2017, Vetvicka et al., 2019).

SUMMARY OF INVENTION

[0009] It has been found, in accordance with the present invention, that a composition comprising CBD, A⁹-THC, CBDV, and CBDA (herein referred to as “a cannabinoid composition ) and a composition comprising a mixture of extracts obtained from Agaricus bisporus, Ganoderma lucidum, Ganoderma lucidum spore, Grifola frondosa, Lentinus edodes, and Trametes versicolor (herein referred to as “a mushroom composition ), each had cytotoxic activity on various breast cancer cell lines, more specifically MCF7, BT474, SKBR3, and MDA-MB231. Moreover, each one of those compositions, when applied to breast cancer cell lines together with a conventional chemotherapeutic agent, more specifically taxol or carboplatin, had a synergistic effect in reducing cell viability compared to application of either the composition or chemotherapeutic agent alone. Based on these data, it is expected that a combination of each one of these compositions, when administered as an adjunctive therapy to a conventional therapy, e.g., a chemotherapy, aimed at treating a breast cancer, will have even a greater synergistic effect increasing or maximizing the efficacy of said conventional therapy.

[0010] In one aspect, the present invention thus relates to a method for treatment of a breast cancer in a subject in need thereof, said subject undergoing a conventional therapy for treating said breast cancer, and said method comprising administering to said subject, as an adjunctive therapy, a cannabinoid composition, a mushroom composition, or a combination of said cannabinoid composition and said mushroom composition, wherein: (i) said cannabinoid composition comprises cannabidiol (CBD) or an enantiomer, diastereomer, or a mixture thereof; A⁹-tetrahydrocannabinol (A⁹-THC) or an enantiomer, diastereomer, or a mixture thereof; cannabidivarin (CBDV) or an enantiomer, diastereomer, or a mixture thereof; cannabidiolic acid (CBDA) or an enantiomer, diastereomer, or a mixture thereof, and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract. In particular embodiments, said cannabinoid composition comprises one or more terpenes, e.g., at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, constituting up to about 3%, e.g., from about 1% to about 2%, by weight of said composition.

[0011] In another aspect, the present invention relates to a cannabinoid composition, a mushroom composition, or a combination of said cannabinoid composition and said mushroom composition, for use as an adjunctive therapy to a conventional therapy in the treatment of a breast cancer, wherein: (i) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or a mixture thereof; A⁹-THC or an enantiomer, diastereomer, or a mixture thereof; CBDV or an enantiomer, diastereomer, or a mixture thereof; CBDA or an enantiomer, diastereomer, or a mixture thereof; and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract. In particular embodiments, said cannabinoid composition comprises one or more terpenes, e.g., at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, constituting up to about 3%, e.g., from about 1% to about 2%, by weight of said composition.

[0012] In a further aspect, the present invention provides a kit comprising a cannabinoid composition, a mushroom composition, and optionally instructions for administration of said compositions, as a combined treatment, for providing an adjunctive therapy to asubject having a breast cancer and undergoing a conventional therapy for treating said breast cancer, wherein: (i) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or a mixture thereof; A⁹-THC or an enantiomer, diastereomer, or a mixture thereof; CBDV or an enantiomer, diastereomer, or a mixture thereof; CBDA or an enantiomer, diastereomer, or a mixture thereof; and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract. In particular embodiments, said cannabinoid composition comprises one or more terpenes, e.g., at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, constituting up to about 3%, e.g., from about 1% to about 2%, by weight of said composition.

BRIEF DESCRIPTION OF DRAWINGS

[0013] Figs. 1A-1C show the effect of a combination of CBD, A⁹-THC, CBDV, and CBDA on cell viability (%) as compared to each one of the cannabinoids when administered alone, in various breast cancer cell lines, more specifically MCF7 (1A), MDA-MB231 (IB), and SKBR3 (1C). The concentration of all cannabinoids is in the low pM range (<10 pM).

[0014] Fig. 2 shows the effect of a combined treatment of a cannabinoid composition and taxol-based chemotherapy on cell viability (%) as compared to each one of the cannabinoid composition and taxol-based chemotherapy, when administered alone, in MCF7 (left panel) and SKBR3 (right panel) breast cancer cell lines.

[0015] Fig. 3 shows the effect of a combined treatment of a mushroom composition and taxol-based chemotherapy on cell viability (%) as compared to each one of the mushroom composition and taxol-based chemotherapy, when administered alone, in MCF7 (left panel) and SKBR3 (right panel) breast cancer cell lines. [0016] Fig. 4 shows the effect of a combined treatment of a mushroom composition and carboplatin-based chemotherapy on cell viability (%) as compared to each one of the mushroom composition and carboplatin-based chemotherapy, when administered alone, in MDA-MB231 breast cancer cell line, at carboplatin concentration of 300 pM (left panel) and 1000 pM (right panel).

DETAILED DESCRIPTION

[0017] In one aspect, disclosed herein is a method for treatment of a breast cancer in a subject in need thereof, said subject undergoing a conventional therapy, e.g., a chemotherapy, for treating said breast cancer, and said method comprising administering to said subject, as an adjunctive therapy, a cannabinoid composition, mushroom composition, or a combination thereof, wherein: (i) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or a mixture, e.g., racemate, thereof; A⁹-THC or an enantiomer, diastereomer, or a mixture, e.g., racemate, thereof; CBDV or an enantiomer, diastereomer, or a mixture, e.g., racemate, thereof; CBDA or an enantiomer, diastereomer, or a mixture, e.g., racemate, thereof; and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of extracts, more specifically an extract of Agaricus bisporus (also referred to herein as “Agaricus bisporus extract”); an extract of Ganoderma lucidum (also referred to herein as Ganoderma lucidum extract”) an extract of Ganoderma lucidum spore (also referred to herein as (lanoderma lucidum spore extract”); an extract of Grifola frondosa (also referred to herein as 'Grifola frondosa extract”); an extract of Lentinus edodes (also referred to herein as Lentinus edodes extract”); and an extract of Trametes versicolor (also referred to herein as Trametes versicolor extract”).

[0018] The term “cannabinoid” as used herein refers to a chemical compound acting on a cannabinoid receptor, i.e., cannabinoid type 1 (CB1) and/or cannabinoid type 2 (CB2) receptor. Ligands for these receptor proteins include the endocannabinoids produced naturally in the body; the phytocannabinoids found in Cannabis saliva. Cannabis indica. Cannabis ruderalis. and some other plants; and synthetic cannabinoids. The term “cannabinoid composition” as used herein denotes a composition, e.g., a nutraceutical or pharmaceutical composition, comprising the four specific cannabinoids listed above, i.e., CBD (2-[(17?,67?)-3-methyl-6-prop-l-en-2-ylcyclohex-2-en-l-yl]-5-pentylbenzene-l,3- diol) or an enantiomer, diastereomer, or a mixture (e.g., racemate) thereof; A⁹-THC (6,6,9- trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c] chromen-l-ol) or an enantiomer, diastereomer, or a mixture (e.g., racemate) thereof; CBDV (2-[( l /?,6/?)-3-mcthyl-6-prop-l - en-2-ylcyclohex-2-en-l-yl]-5-propylbenzene-l,3-diol) or an enantiomer, diastereomer, or a mixture (e.g., racemate) thereof; CBDA (2,4-dihydroxy-3-[(lR,6R)-3-methyl-6-prop-l-en- 2-ylcyclohex-2-en-l-yl]-6-pentylbenzoic acid) or an enantiomer, diastereomer, or a mixture (e.g., racemate) thereof; and optionally one or more terpenes. Preferred cannabinoid compositions comprise CBD, A⁹-THC, CBDV and CBDA. Yet, for the sake of simplicity and if not otherwise explicitly specified, all references made throughout this specification to any one of CBD, A⁹-THC, CBDV and CBDA independently refers to an enantiomer, diastereomer, or a mixture, e.g., racemate, of said cannabinoid. The overall amount by weight of the cannabinoids composing the cannabinoid composition, i.e., the sum of weight amounts of CBD, A⁹-THC, CBDV, CBDA, is referred to herein as “total cannabinoids”.

[0019] Administration of A⁹-THC, which is the primary psychotropic constituent of cannabis, is associated with undesirable effects such as tachycardia, anxiety, altered cognitive perception, and other behavioral issues, and has a maximum tolerated daily dose of only 15-90 mg in adults. According to the literature, A⁹-THC reduces cell viability, cell proliferation, invasion and tumor growth both in vitro and in vivo (Takeda et al., 2013; Ligresti et al., 2006; Murase et al., 2014). Preclinical studies have established that A⁹-THC inhibits the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1-R and CB2-R), and is capable of reducing human breast cancer cell proliferation by blocking the progression of the cell cycle and inducing apoptosis through activation of CB2-R (Caffarel et al., 2006). Additionally, A⁹-THC reduced tumor growth and the amount/severity of lung metastases in a genetically engineered animal model of ErbB2-driven metastatic breast cancer (MMTV-neu mice) (Caffarel et al., 2010); and disrupted human epidermal growth factor receptor 2 (HER2)- CB2-R complexes by selectively binding to CB2-R, which leads to the inactivation of HER2 through disruption of HER2-HER2 homodimers, and the subsequent degradation of HER2. Such activity triggers antitumor responses in vitro and in vivo (Blasco-Benito et al., 2019). On the other hand, it has been shown that A⁹-THC may alter the immune system function and increase the susceptibility of a patient to microbial infections; and in spite of its demonstrated anti-cancer properties, under certain circumstances it may promote tumor growth, invasion and metastasis in some cancer cell types. In breast cancer, for example, A⁹-THC-mediated increased tumor growth and metastasis was associated with inhibition of the anti-tumor specific immune responses in vivo (McKallip et al., 2005). A retrospective analysis further demonstrated that cannabis use is associated with the markedly reduced effectiveness of immune checkpoint inhibitors (Taha et al., 2019).

[0020] In contrast to A⁹-THC, CBD, which is the second most abundant cannabinoid in cannabis, is well-tolerated in patients even at relatively high doses. CBD has demonstrated robust anti-proliferative and pro-apoptotic effects on a wide variety of cancer types, including breast cancer, both in cultured cancer cell lines and in mouse tumor models, while having milder effects on normal cells from the same tissue/organ (McAllister et al., 2007; Shrivastava et al., 2011; Sultan et al., 2018). More specifically, CBD induced significant cell death in human breast adenocarcinoma cell line MDA-MB-231 after 24 h at low doses of 1 to 5 pM, inhibited the survival of both estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines, and induced apoptosis in a concentration-dependent manner. Moreover, at said concentrations, CBD had little effect on the nontumorigenic mammary (MCF-10A) cells (Kosgodage et al., 2018). According to Selzer et al., 2020, CBD can also inhibit tumor migration, invasion and neovascularization, suggesting that it not only acts on tumor cells but can also affect the tumor microenvironment, e.g., by modulating infiltrating mesenchymal cells and immune cells.

[0021] The anticancer activity of CBDA has been preliminarily tested on CEM (acute lymphocytic leukemia) and HL60 (promyelocytic leukemia) cells, and the effect of CBDA was evaluated on cell viability, cell proliferation, and cell-cycle dynamics. Data from those experiments, as well as from MTT assay on human prostate carcinoma androgen receptorpositive (LNCaP) cells (De Petrocellis et al., 2013), evidenced that CBDA was less active than CBD. Yet, it has been shown that CBDA inhibits the enzymatic activity of cyclooxygenase-2 (COX-2), an enzyme involved in inflammatory processes and in the metastasis of cancer cells, with an IC50 value of 2.2 M, and diminishes the expression of COX-2 in human breast cancer MDA-MB-231 cells, a highly aggressive triple-negative breast cancer cell line (Formato et al., 2020; Takeda et al., 2017). As further shown, CBDA inhibited the MDA-MB-231 breast cancer cell migration, and the mechanism responsible for the inhibitory effects likely involves activation of small GTPase RhoA via inhibition of a c AMP-dependent protein kinase (PKA) (Takeda et al., 2012). [0022] CBDV is a minor cannabinoid and is a structural analogue of CBD, more specifically a propyl analogue of CBD. Due to the absence of psychotropic activity and its promising utility as an anticonvulsive agent, CBDV has a great therapeutic potential. In particular, and in spite of the lack of information about its mechanism of action, CBDV is being tested in pre-clinical studies for autism spectrum disorders (ASD) and childhood epilepsy (Alves et al., 2020). In addition, CBDV was found as a potent inhibitor of 1-a- lysophosphatidylinositol (LPI)-induced G protein-coupled receptor 55 (GPR55) signaling. This receptor is involved in the migratory behavior of human breast cancer cells and could thus serve as a pharmacological target for preventing metastasis (Zhou et al., 2018; Anavi- Goffer et al., 2012).

[0023] According to the present invention, each one of the cannabinoids comprised within the cannabinoid composition, i.e., CBD, A⁹-THC, CBDV, and CBDA, may independently derive from a Cannabis extract, e.g., Cannabis Sativa extract, using any suitable extraction and purification procedures known in the art, or may alternatively be synthesized following any one of the procedures disclosed in the literature.

[0024] In certain embodiments, the cannabinoid composition comprises CBD in an amount of from about 12% to about 32%, preferably from about 17% to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids; A⁹-THC in an amount of from about 3% to about 23%, preferably from about 8% to about 18%, more preferably from about 11% to about 15%, e.g., from about 12% to about 14%, by weight of total cannabinoids; CBDV in an amount of from about 33% to about 53%, preferably from about 38% to about 48%, more preferably from about 41% to about 45%, e.g., from about 42% to about 44%, by weight of total cannabinoids; and CBDA in an amount of from about 12% to about 32%, preferably from about 17% to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids. In particular embodiments, said cannabinoid composition comprises CBD in an amount of about 22% by weight of total cannabinoids; A⁹-THC in an amount of about 13% by weight of total cannabinoids; CBDV in an amount of about 43% by weight of total cannabinoids; and CBDA in an amount of about 22% by weight of total cannabinoids.

[0025] In certain embodiments, the cannabinoid composition according to any one of the embodiments above comprises one or more, e.g., two, three, four, or five, terpenes constituting up to about 3%, e.g., from about 0.25% to about 2.5%, from about 0.5% to about 2%, from about 0.75% to about 1.5%, or about 1%, by weight of said cannabinoid composition. The term “total terpenes” as used herein refers to the overall amount by weight of the terpenes, i.e., the sum of weight amounts of all terpenes comprised within said cannabinoid composition.

[0026] The term “terpene” as used herein refers to a hydrocarbon produced by a variety of plants and by some insects. Terpenes often have a strong odor and may protect the plants producing them by deterring herbivores and by attracting predators and parasites of herbivores. Terpenes are also major biosynthetic building blocks. Steroids, for example, are derivatives of the triterpene squalene. Modified terpenes, i.e., terpenes containing a functional group, usually an oxygen-containing group, are called terpenoids or isoprenoids. The terpenes optionally comprised within the cannabinoid composition as defined herein may independently be either naturally produced and optionally purified, or synthetic.

[0027] Terpenes and terpenoids are the primary constituents of the essential oils of many types of plants and flowers. Essential oils are used widely as fragrances in perfumery and traditional medicine, such as aromatherapy. Synthetic variations and derivatives of natural terpenes and terpenoids also greatly expand the variety of aromas used in perfumery and flavors used in food additives.

[0028] Monoterpenes are a class of terpenes consisting of two isoprene units and having the molecular formula C10H16. Monoterpenes may be linear (acyclic) or contain rings (cyclic). Modified terpenes, such as those containing oxygen functionality or missing a methyl group, are called monoterpenoids. Monoterpenes and monoterpenoids are used in the pharmaceutical, cosmetic, agricultural, and food industries. Non-limiting examples of monoterpenes or monoterpenoids comprised within the terpene combination of the invention include a pinene selected from a-pinene, P-pinene, and y-pinene, limonene, linalool, myrcene, camphene, nerol, geraniol, a terpineol selected from a-terpineol, P- terpineol, y-terpineol, and terpinen-4-ol, or an enantiomer or diastereomer thereof.

[0029] Sesquiterpenes are a class of terpenes consisting of three isoprene units and often have the molecular formula C15H24. Like monoterpenes, sesquiterpenes may be acyclic or contain rings, including many unique combinations. Biochemical modifications such as oxidation or rearrangement produce the related sesquiterpenoids. Non-limiting examples of sesquiterpene or sesquiterpenoid include longifolene, copaene, patchoulol, farnesol, humulene, famesene, P-caryophyllene, or an enantiomer or diastereomer thereof. [0030] In particular embodiments, said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene. In more particular embodiments, said terpenes comprise three or four of the specific terpenes listed above, i.e., linalool, limonene and a-pinene; linalool, limonene and P-caryophyllene; linalool, limonene and P-myrcene; limonene, a-pinene and P-caryophyllene; limonene, a-pinene and P-myrcene; a-pinene, P-caryophyllene, and P-myrcene; linalool, limonene, a-pinene, and P-caryophyllene; linalool, limonene, a-pinene, P-myrcene; or limonene, a-pinene, P- caryophyllene, and P-myrcene. Preferred embodiments are those wherein said terpenes comprise all five specific terpenes listed above, i.e., linalool, limonene, a-pinene, P- caryophyllene, and P-myrcene, preferably at equal amounts, i.e., wherein each of said terpenes constitutes about 20% by weight of total terpenes.

[0031] Medicinal mushrooms have become an attractive source of functional food and therapeutic products mainly because of their chemical composition. It is established that, undoubtedly, mushrooms have the greatest potential for medical and pharmaceutical use due to their ability to synthesize many highly beneficial bioactive compounds and could be a great source of bioactive substances such as essential amino acids, fatty acids, dietary fiber, polysaccharides (mainly P-glucans), vitamins, micro- and macro -elements, lectins, terpenoids, steroids, statins, phenols, alkaloids, and antibiotics (Cohen et al., 2014, Wasser 2018, Xue et al., 2020).

[0032] Many, if not all, medicinal mushrooms contain biologically active compounds in fruit bodies, cultured mycelium, and cultured broth.

[0033] Medicinal mushrooms are comparable to “medicinal plants” and can be defined as macroscopic fungi, mostly higher Basidiomycetes and some Ascomycetes, which are used in the form of extracts or powder for prevention, alleviation, or healing multiple diseases, and/or in balancing a healthy diet. According to the definition of “herbal drugs”, dried fruit bodies, my celia, or spores are considered “mushroom drugs” or “fungal drugs”. Analogous to “phytopharmaceuticals” or “herbal preparations”, the resulting mushrooms preparations should be considered as “mushroom pharmaceuticals”, “mushroom drugs” or “mushroom preparations”. New class of drugs were developed from MMs called “mushroom pharmaceuticals or mushroom drugs”, or biological response modifiers (BRMs) like krestin (PSK) and PSP (polysaccharide peptide) from Trametes versicolor, lentinan, isolated from Lentinus edodes', schizophyllan (sonifilan, sizofiran, or SPG) from Schizophyllum commune', befungin from Inonotus obliquus', D-fraction from Grifola frondosa, GLPS polysaccharide fraction from Ganoderma lucidum', active hexose correlated compound (AHCC), and some others (Wasser, 2010, Chang and Wasser, 2018). [0034] Several of the mushroom compounds have proceeded through Phase I, II, III, and IV clinical trials and are used extensively and successfully in Asia to treat various cancers and other diseases. Approximately 300 clinical studies were conducted only on Ganoderma lucidum and some other species of the genus Ganoderma. Most of the clinical trials were done mainly using G. lucidum, Lentinus edodes, Grifola frondosa, Trametes versicolor, Schizophyllum commune, Phellinus linteus, and Agaricus brasiliensis for treatment of cancers, oncoimmunological, and immunological diseases and in immune- adjuvant therapy. Fruiting bodies of mushrooms and/or their biomass from submerged cultivated mycelia, different types of extracts, rare spores (from G. lucidum), and pure P- glucans (e.g., lentinan or schizophyllan isolated from cultural broth), or proteoglucan (PSK) or polysaccharide peptide (PSP) have been used in clinical trials for cancer treatment.

[0035] The term “mushroom composition” as used herein denotes a composition, e.g., a nutraceutical or pharmaceutical composition, comprising extracts obtained from the five medicinal mushrooms listed above, i.e., Agaricus bisporus, Ganoderma lucidum, Grifola frondosa, Lentinus edodes, and Trametes versicolor. The overall amount by weight of the extracts composing the mushroom composition, i.e., the sum of weight amounts of Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract, is referred to herein as “total extracts”.

[0036] The term “Agaricus bisporus extract” as used herein refers to an extract of Agaricus bisporus fruiting bodies, which is rich in polysaccharides, i.e., comprises at least 27%, preferably at least 30%, polysaccharides originated from said mushroom. In certain embodiments, said extract is obtained by extracting fruiting bodies of said mushroom with water, e.g., at a temperature in a range of 20-90°C, preferably 30-70°C. In a particular embodiment exemplified herein, said extract is the commercial product manufactured by Zhejiang Suichang Limin Pharmaceutical Co. Ltd., Yunfeng Food Branch, China, which includes at least 30% polysaccharides, about 25% proteins, and about 0.5% fats.

[0037] The term “Ganoderma lucidum extract” as used herein refers to an extract of Ganoderma lucidum fruiting bodies and/or mycelium, which is rich in polysaccharides and triterpenes (also referred to as “ganoderic acids”), i.e., comprises at least 24%, preferably at least 27%, polysaccharides, and at least 4%, preferably at least 4.5%, triterpenes, originated from said mushroom. In certain embodiments, said extract is obtained by extracting fruiting bodies and/or mycelium of said mushroom with an alcohol such as ethanol, at a temperature in a range of 20-90°C, preferably 30-70°C. In a particular embodiment exemplified herein, said extract is the commercial product (GLAE) manufactured by Zhejiang Suichang Limin Pharmaceutical Co. Ltd., Yunfeng Food Branch, China, which includes at least 30% polysaccharides, about 25% proteins, at least 5% triterpenes, and about 0.5% fats.

[0038] The term “Ganoderma lucidum spore extract” as used herein refers to an extract of Ganoderma lucidum spores/fruiting bodies, which is rich in adenosine/triterpene, i.e., comprises at least 16%, preferably at least 20%, adenosine/triterpenes originated from said mushroom (such extract is also referred to herein as “ Ganoderma lucidum spore oil”). In certain embodiments, said extract is obtained by extracting spores/fruiting bodies of said mushroom with CO2. In a particular embodiment exemplified herein, said extract is the commercial product manufactured by Hangzhou Johncan Mushroom Bio-Technology Co. Ltd., China, which includes about 22% adenosine/triterpene and about 2% polysaccharides. [0039] The term “Grifola frondosa extract” as used herein refers to an extract of Grifola frondosa fruiting bodies, which is rich in beta-glucans and polysaccharides, i.e., comprises at least 40%, preferably at least 45%, beta-glucans; and at least 28%, preferably at least 32%, polysaccharides, originated from said mushroom. In certain embodiments, said extract is obtained by extracting fruiting bodies of said mushroom with water, e.g., at a temperature in a range of 20-90°C, preferably 30-70°C (such extract is also referred to herein as “Grifola frondosa D-fraction extract”, indicating protein-bound p-glucans). In a particular embodiment exemplified herein, said extract is the commercial product manufactured by Hangzhou Johncan Mushroom Bio-Technology Co. Ltd., China, which includes about 51% beta-glucans and about 36% polysaccharides.

[0040] The term “Lentinus edodes extract” as used herein refers to an extract of Lentinus edodes fruiting bodies, which is rich in polysaccharides, i.e., comprises at least 28%, preferably at least 32%, polysaccharides originated from said mushroom. In certain embodiments, said extract is obtained by extracting fruiting bodies of said mushroom with water, e.g., at a temperature in a range of 20-90°C, preferably 30-70°C. In a particular embodiment exemplified herein, said extract is the commercial product manufactured by Zhejiang Suichang Limin Pharmaceutical Co. Ltd., Yunfeng Food Branch, China, which includes at least 30% polysaccharides, about 24.5% proteins, and about 0.5% fats.

[0041] The term “Trametes versicolor extract” as used herein refers to an extract of Trametes versicolor mycelium, which is rich in polysaccharides, i.e., comprises at least 24%, and preferably at least 27%, polysaccharides originated from said mushroom. In certain embodiments, said extract is obtained by extracting mycelium of said mushroom with water, e.g., at a temperature in a range of 20-90°C, preferably 30-70°C, and filtering the crude product thus obtained to obtain a product having at least 50% of polysaccharides having a molecular weight greater than 40000 Dalton (such extract is also referred to herein as “Trametes versicolor pure krestin extract”). In a particular embodiment exemplified herein, said extract is the commercial product manufactured by Zhejiang Suichang Limin Pharmaceutical Co. Ltd., Yunfeng Food Branch, China, which includes at least 30% polysaccharides, about 25% proteins, and about 0.5% fats.

[0042] In certain embodiments, the mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25%, preferably from about 10% to about 20%, more preferably from about 13% to about 17%, e.g., from about 14% to about 16%, by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38%, preferably from about 23% to about 33%, more preferably from about 26% to about 30%, e.g., from about 27% to about 29%, by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3%, preferably from about 1.5% to about 2.5%, more preferably from about 1.75% to about 2.25%, by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24%, preferably from about 9% to about 19%, more preferably from about 12% to about 16%, e.g., from about 13% to about 15%, by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33%, preferably from about 18% to about 28%, more preferably from about 21% to about 25%, e.g., from about 22% to about 24%, by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29%, preferably from about 14% to about 24%, more preferably from about 17% to about 21%, e.g., from about 18% to about 20%, by weight of total extracts. In particular embodiments, said mushroom composition comprises Agaricus bisporus extract in an amount of about 15% by weight of total extracts, Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, Grifola frondosa extract in an amount of about 14% by weight of total extracts, Lentinus edodes extract in an amount of about 23% by weight of total extracts, and Trametes versicolor extract in an amount of about 19% by weight of total extracts.

[0043] In certain embodiments, the method of the present invention comprises administering to said subject, as an adjunctive therapy, a cannabinoid composition, mushroom composition, or combination thereof, wherein said cannabinoid composition comprises CBD in an amount of from about 12% to about 32%, preferably from about 17& to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids; A⁹-THC in an amount of from about 3% to about 23%, preferably from about 8% to about 18%, more preferably from about 11% to about 15%, e.g., from about 12% to about 14%, by weight of total cannabinoids; CBDV in an amount of from about 33% to about 53%, preferably from about 38% to about 48%, more preferably from about 41% to about 45%, e.g., from about 42% to about 44%, by weight of total cannabinoids; and CBDA in an amount of from about 12% to about 32%, preferably from about 17% to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids; and said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25%, preferably from about 10% to about 20%, more preferably from about 13% to about 17%, e.g., from about 14% to about 16%, by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38%, preferably from about 23% to about 33%, more preferably from about 26% to about 30%, e.g., from about 27% to about 29%, by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3%, preferably from about 1.5% to about 2.5%, more preferably from about 1.75% to about 2.25%, by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24%, preferably from about 9% to about 19%, more preferably from about 12% to about 16%, e.g., from about 13% to about 15%, by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33%, preferably from about 18% to about 28%, more preferably from about 21% to about 25%, e.g., from about 22% to about 24%, by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29%, preferably from about 14% to about 24%, more preferably from about 17% to about 21%, e.g., from about 18% to about 20%, by weight of total extracts. In particular embodiments, said cannabinoid composition comprises CBD in an amount of about 22% by weight of total cannabinoids; A⁹-THC in an amount of about 13% by weight of total cannabinoids; CBDV in an amount of about 43% by weight of total cannabinoids; and CBDA in an amount of about 22% by weight of total cannabinoids; and said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

[0044] In certain embodiments, the cannabinoid composition referred to hereinabove comprises one or more terpenes constituting up to about 3%, e.g., from about 0.25% to about 2.5%, from about 0.5% to about 2%, from about 0.75% to about 1.5%, or about 1%, by weight of said cannabinoid composition. In particular such embodiments, said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, more particularly three or four of said terpenes, i.e., linalool, limonene and a- pinene; linalool, limonene and P-caryophyllene; linalool, limonene and P-myrcene; limonene, a-pinene and P-caryophyllene; limonene, a-pinene and P-myrcene; a-pinene, P- caryophyllene, and P-myrcene; linalool, limonene, a-pinene, and P-caryophyllene; linalool, limonene, a-pinene, P-myrcene; or limonene, a-pinene, P-caryophyllene, and P-myrcene. In preferred such embodiments, said terpenes comprises linalool, limonene, a-pinene, P- caryophyllene, and P-myrcene, preferably at equal amounts, i.e., wherein each of said terpenes constitutes about 20% by weight of total terpenes.

[0045] The composition or compositions administered according to the method disclosed herein may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19^th Ed., 1995. More specifically, such compositions may be prepared, e.g., by uniformly and intimately bringing the active agents, i.e., the cannabinoids or the mixture of mushroom extracts, into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation. The compositions may independently be in liquid, solid or semisolid form and may further include various acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients.

[0046] In certain embodiments, each one of the compositions administered may independently be either a pharmaceutical or nutraceutical composition, optionally further comprising a pharmaceutically or nutraceutically acceptable carrier, respectively. Particular such compositions are formulated for either oral or oral mucosal (e.g., sublingual, supra-lingual, or buccal) administration, or for inhalation. More particular such compositions are formulated as a liquid dosage form, e.g., a solution, emulsion, syrup, or elixir; or as a solid dosage form, e.g., a tablet, capsule, or pill. In particular embodiments, both the cannabinoid composition and the mushroom compositions are nutraceutical compositions formulated each independently as either a liquid dosage form (e.g., a solution, emulsion, syrup, or elixir); or as a solid dosage form (e.g., a tablet, capsule, or pill).

[0047] In certain embodiments, the method of the present invention comprises administering to said subject, as an adjunctive therapy, only one of the compositions referred to above, i.e., either a cannabinoid composition or a mushroom composition, each according to any one of the embodiments above.

[0048] In other embodiments, the method of the present invention comprises administering to said subject, as an adjunctive therapy, a combination of said cannabinoid composition and said mushroom composition, according to any one of the embodiments above. According to the present invention, the cannabinoid composition and the mushroom composition administered as a combination may be formulated as two separate compositions for the same or different administration mode, and may thus be administered concomitantly, or sequentially at any order. Alternatively, said compositions may be formulated as a sole composition, e.g., a sole pharmaceutical or nutraceutical composition. [0049] The compositions disclosed herein are for use either alone or in combination, as an adjunctive therapy to a conventional therapy aimed at treating a breast cancer.

[0050] The terms “conventional therapy” and “conventional treatment”, as used herein interchangeably, refer to any conventional treatment of cancer, more specifically breast cancer, by the use of a chemotherapy, hormonotherapy, immunotherapy, tyrosine kinase inhibitor-based therapy, antiangiogenic based-therapy, antibody-based therapy, or any combination thereof. The terms “conventional chemotherapy”, “conventional chemotherapeutic treatment”, and “chemotherapy”, as used herein interchangeably, refer to a chemotherapy-based conventional therapy for treatment of breast cancer, and mean administration of one or more chemotherapeutic agents/drugs, to a subject in need thereof, following any treatment regimen known in the art. [0051] In certain embodiments, the conventional therapy referred to herein is a chemotherapy comprising administration of a taxane, e.g., paclitaxel (Taxol®), albumin paclitaxel (Abraxane®), and docetaxel (Taxotere®); a nonsteroidal aromatase inhibitor, e.g., anastrozole (Arimidex®), letrozole (Femara®), and tamoxifen (Soltamox®); an anthracycline, e.g., doxorubicin (Adriamycin®), liposomal doxorubicin (Doxil®), and epirubicin (Ellence®); platinum-based agents, e.g., cisplatin and carboplatin; or antibody drug conjugates, e.g., ado-trastuzumab emtansine (Kadcyla®), fam-trastuzumab deruxtecan (Enhertu®), and sacituzumab govitecan (Trodelvy®).

[0052] The term “adjunctive therapy” as used herein refers to a therapy given to a subject having a breast cancer and undergoing a conventional therapy for treating said breast cancer, in addition and in parallel to said conventional therapy, so as to increase or maximize the efficacy of said conventional therapy.

[0053] The breast cancer treated by the method disclosed herein may be any type of breast cancer currently known such as, without being limited to, luminal A breast cancer, luminal B breast cancer, human epidermal growth factor receptor 2 (HER2) -positive breast cancer, and triple-negative breast cancer.

[0054] The term "subject" as used herein refers to any mammal, e.g., a human, nonhuman primate, horse, ferret, dog, cat, cow, and goat. In a preferred embodiment, the term "subject" denotes a human, i.e., an individual.

[0055] In another aspect, the present invention relates to a cannabinoid composition, mushroom composition, or a combination thereof, for use as an adjunctive therapy to a conventional therapy, e.g., a chemotherapy, in the treatment of a breast cancer, wherein: (i) said cannabinoid composition comprises CBD, A⁹-THC, CBDV, CBDA, and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of extracts, more specifically an Agaricus bisporus extract, a Ganoderma lucidum extract, a Ganoderma lucidum spore extract, a Grifola frondosa extract, a Lentinus edodes extract, and a Trametes versicolor extract.

[0056] The cannabinoid composition and the mushroom composition used, either alone or in combination, as an adjunctive therapy to a conventional therapy, according to this aspect of the present invention, are each as defined in any one of the embodiments above.

[0057] In certain embodiments, said cannabinoid composition comprises CBD in an amount of from about 12% to about 32%, preferably from about 17% to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids; A⁹-THC in an amount of from about 3% to about 23%, preferably from about 8& to about 18%, more preferably from about 11% to about 15%, e.g., from about 12% to about 14%, by weight of total cannabinoids; CBDV in an amount of from about 33% to about 53%, preferably from about 38% to about 48%, more preferably from about 41% to about 45%, e.g., from about 42% to about 44%, by weight of total cannabinoids; and CBDA in an amount of from about 12% to about 32%, preferably from about 17% to about 27%, more preferably from about 20% to about 24%, e.g., from about 21% to about 23%, by weight of total cannabinoids; and said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25%, preferably from about 10% to about 20%, more preferably from about 13% to about 17%, e.g., from about 14% to about 16%, by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38%, preferably from about 23% to about 33%, more preferably from about 26% to about 30%, e.g., from about 27% to about 29%, by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3%, preferably from about 1.5% to about 2.5%, more preferably from about 1.75% to about 2.25%, by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24%, preferably from about 9% to about 19%, more preferably from about 12% to about 16%, e.g., from about 13% to about 15%, by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33%, preferably from about 18% to about 28%, more preferably from about 21% to about 25%, e.g., from about 22% to about 24%, by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29%, preferably from about 14% to about 24%, more preferably from about 17% to about 21%, e.g., from about 18% to about 20%, by weight of total extracts. In particular embodiments, said cannabinoid composition comprises CBD in an amount of about 22% by weight of total cannabinoids; A⁹-THC in an amount of about 13% by weight of total cannabinoids; CBDV in an amount of about 43% by weight of total cannabinoids; and CBDA in an amount of about 22% by weight of total cannabinoids; and said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

[0058] In certain embodiments, the cannabinoid composition referred to hereinabove comprises one or more terpenes constituting up to about 3%, e.g., from about 0.25% to about 2.5%, from about 0.5% to about 2%, from about 0.75% to about 1.5%, or about 1%, by weight of said cannabinoid composition. In particular such embodiments, said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, more particularly three or four of said terpenes, i.e., linalool, limonene and a- pinene; linalool, limonene and P-caryophyllene; linalool, limonene and P-myrcene; limonene, a-pinene and P-caryophyllene; limonene, a-pinene and P-myrcene; a-pinene, P- caryophyllene, and P-myrcene; linalool, limonene, a-pinene, and P-caryophyllene; linalool, limonene, a-pinene, P-myrcene; or limonene, a-pinene, P-caryophyllene, and P-myrcene. In preferred such embodiments, said terpenes comprises linalool, limonene, a-pinene, P- caryophyllene, and P-myrcene, preferably at equal amounts, i.e., wherein each of said terpenes constitutes about 20% by weight of total terpenes.

[0059] In certain embodiments, the present invention relates to only one of the compositions referred to above, i.e., either a cannabinoid composition or a mushroom composition, each according to any one of the embodiments above, for use as an adjunctive therapy to a conventional therapy in the treatment of a breast cancer.

[0060] In other embodiments, the present invention relates to a combination of said cannabinoid composition and said mushroom composition, according to any one of the embodiments above, for use as an adjunctive therapy to a conventional therapy in the treatment of a breast cancer. According to the present invention, said compositions may be formulated as two separate compositions for the same or different administration mode, which are to be administered concomitantly, or sequentially at any order. Alternatively, said compositions may be formulated as a sole composition, e.g., a sole pharmaceutical or nutraceutical composition.

[0061] In a further aspect, the present invention provides a kit comprising a cannabinoid composition, a mushroom composition, and optionally instructions for administration of said compositions, as a combined treatment, for providing an adjunctive therapy to a subject having a breast cancer and undergoing a conventional therapy for treating said breast cancer, wherein: (i) said cannabinoid composition comprises CBD, A⁹-THC, CBDV, CBDA, and optionally one or more terpenes; and (ii) said mushroom composition comprises a mixture of extracts, more specifically Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract.

[0062] Unless otherwise indicated, all numbers expressing, e.g., amounts of components in the compositions referred to or temperature, used in this specification, are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification are approximations that may vary by up to plus or minus 10% depending upon the desired properties to be obtained by the present invention.

[0063] The invention will now be illustrated by the following non-limiting Examples.

EXAMPLES

Materials and Methods

[0064] Mushroom extracts. Trametes versicolor Pure Krestin Extract (lot number S200528001), Lentinus edodes extract (lot number S200408002), Agaricus bisporus extract (lot number S200408002), and Ganoderma lucidum extract (GLAE, lot number S201016002) were supplied by Zhejiang Suichang Limin Pharmaceutical Co. Ltd. Yunfeng Food Branch, China. Grifola frondosa D-fraction extract (Matakei Extract, batch number 0/HSH-FE20200901-S08,) and Ganoderma lucidum spore extract (Reishi spore oil, batch number 0/LZBZY-FT20200701-S13) were supplied by Hangzhou Johncan Mushroom Bio-Technology Co. Ltd., China.

[0065] Cannabinoids. Cannabinoids for the studies described in Examples 1-4 were provided by Lumir Lab, Israel. The THC used in study described in Example 5 is dronabinol (a synthetic product); CBD (>98%) was provided by Mile High Labs (International Ltd, Falcon Way, Belfast, Northern Ireland, BT12 6SQ); and CBDA (>97%) and CBDV (99.9%) were provided by Precision Plant Molecules (PPM, 2300 E 76^th Avenue Suite D-100, Welby, CO 80229 United States).

Example 1. Preparation of the mushroom composition

[0066] The content of the extracts comprised within the mushroom composition is detailed in Table 1. Table 1. The content of the mushroom composition prepared

Example 2. Preparation of the cannabinoid composition

[0067] The cannabinoid composition was prepared by re-suspending the cannabinoids CBDA, CBD, CBDV, and THC in dimethyl sulfoxide (DMSO), to obtain a stock concentration of 100 mM for each one of the cannabinoids. The concentration of each one of the cannabinoids in the final composition is described in Table 2.

Table 2. The content of the cannabinoid composition prepared

[0068] Fresh cannabinoids mix was prepared before every set of experiments.

Example 3. Cytotoxic activity of the cannabinoid and mushroom compositions on various breast cancer cell-lines

Materials and methods.

[0069] Cells culture and treatments. Cell lines were cultured according to standard mammalian tissue culture protocols and sterile technique. Human adenocarcinoma breast cancer cell lines MCF-7, MDA-MB-231, SK-BR-3, and BT-747 were cultured in cellspecific media (DMEM for MCF-7 and MDA-MB-231 cells, McCoy's 5A for SK-BR-3 cells, and Hybri-care media for BT-747). All media were supplemented with 10% fetal bovine serum, streptomycin (100 mg/ml), penicillin (100 U/ml) and nystatin (12.5 U/ml). Cells were incubated in 5% CO2 at 37°C. All tissue culture cells were maintained in 75 cm² cell culture treated flask (Eppendorf) and all the media and supplements were obtained from Biological Industries. [0070] Determination of cells viability using MTT assay. The viability of the cells following treatment was determined using a commercially available MTT assay kit (Abeam, ab 146345) and performed according to manufacturer's instructions. Briefly, cells were seeded in a 96-well plate at a density of 2x104 cells/well (n=4) in 100 pl cell specific media. After overnight incubation, cells were exposed to varying concentrations of cannabis samples in lOOpl of specific media. Then, plates were incubated in a humidified atmosphere containing 5% CO2 in air at 37°C for 24 hours. According to the MTT standard protocol, after 24h treatment, the media was removed, and all cells were incubated with serum-free media containing 0.5 mg/ml MTT for 4 hours at the incubator. The MTT purple crystals formed by the viable cells were dissolved using isopropanol containing 0.04 mol/L HC1. The quantification was determined by measuring the optical density at 570 nm in a spectrophotometer reader (Spark, Tecan). Results were presented as proportional viability (%) by comparing between treated and untreated groups.

[0071] 30 pM concentration was prepared in a drug-containing DMEM serum-free media from the stock solution mix (30 mM for the CBDV compound) and subsequent dilutions of 1 :2 ratio were performed to obtain lOpM, 3pM, IpM, 0.3 pM and 0.1 pM.

[0072] The cytotoxic activity of the tested mushroom composition and cannabinoid composition (as depicted in Tables 1 and 2, respectively) on MCF7, SKBR3, BT474, and MDA-MB231 cell lines is shown in Table 3.

Table 3. Cytotoxic activity of the tested compositions on various breast cancer cell types

[0073] Results. Each one of the cannabinoid- and mushroom-compositions had a cytotoxic activity in all breast cancer cell lines tested.

Example 4. The combined effect of each one of the cannabinoid- and mushroomcompositions with a chemotherapeutic agent on selected breast cancer cell lines

The combined effect of the cannabinoid composition and taxol on MCF7 and SKBR3 cell lines [0074] Results. The cell viability (%) of MCF7 and SKBR3 cell lines following administration of a combination of the cannabinoid composition (Table 2) and taxol (0.3 pM) as compared to the administration of the cannabinoid composition and taxol, each separately, is shown in Fig. 2. The combined treatment had synergistic effect as compared to the administration of the cannabinoid composition and taxol only, and reduced the MCF7 cells viability to about 40%.

The combined effect of the mushroom composition and taxol on MCF7 and SKBR3 cell lines

[0075] Results. The cell viability (%) of MCF7 and SKBR3 cell lines following administration of a combination of the mushroom composition (Table 1) and taxol (0.3 pM) as compared to the administration of the mushroom composition and taxol, each separately, is shown in Fig. 3. In both cases, the combined treatment had synergistic effect as compared to the administration of the mushroom composition and taxol only, and reduced the MCF7 and SKBR3 cell viability to about 35% and 70%, respectively.

The combined effect of the mushroom composition and carboplatin on MDA-MB231 cell line

[0076] Results. The cell viability of MDA-MB231 cell line following administration of a combination of the mushroom composition (Table 1) and carboplatin as compared to the administration of the mushroom composition and carboplatin, each separately, at two different concentrations of carboplatin (300 and 1000 pM), is shown in Fig. 4. The combined treatment, at both carboplatin concentrations, had synergistic effect as compared to the administration of the mushroom composition and carboplatin only, and reduced the MDA-MB231 cell viability to about 38% and 20%, respectively.

Example 5. The anti-neoplastic activity of combinations of the cannabinoid- and mushroom compositions, administered with taxol, on breast cancer samples

[0077] The present study is aimed at testing the anti-neoplastic activity of a cannabinoid composition as disclosed herein, more specifically the composition shown in Table 4 and identified herein as CNTC 10401; a mushroom composition as disclosed herein, more specifically the composition shown in Table 5 and herein identified CNTC20401; when administered separately, in combination, or in combination and in addition to taxol, on breast cancer samples (ER+/Her2-, triple negative (TN)), i.e., individual patient’s tumor tissue obtained by either biopsy or surgery.

[0078] Evaluation is carried out using the cResponse™ platform (https://www.curesponse.com), which is an Ex Vivo Organ Culture System that uniquely maintains the tissue’s 3D structure and the tumor microenvironment (TME), including stromal cells and the immune system, and thus allows evaluation of drug efficacy in living tumor tissue with an intact TME. This is important as many components in the TME, e.g., immune cells, stromal cells and extracellular matrix proteins, were shown to directly affect the response of cancer cells to anticancer drugs. The cResponse™ platform also allows for long-term tumor culture with high viability and tissue preservation. This is important since many drugs require several days in culture to achieve maximum efficacy. Using this platform enables assessing the response of various treatments and treatment combinations on a single specimen - reflecting the complexity of real- world patients.

[0079] The technology has been calibrated using hundreds of human cancer tissues in Europe, the UK and Israel, and the cResponse™ test is approved for use by the Israeli ministry of health and covered by Israeli insurance companies and healthcare providers. Curesponse is ISO15189 certified (Gavert et al., 2022; Salpeter et al., 2021).

[0080] A calibration experiment was first conducted to determine the concentration of the cannabinoid composition to be used during the main study. The dilution series of the specified cannabinoid composition tested are listed in Table 4.

Table 4. Dilution series of the specified cannabinoid composition tested

[0081] Comparison of treatments/concentrations using the cResponse™ platform is based on a score, which reflects the responsiveness of the tissue to the treatment, and is determined by curesponse proprietary algorithm integrating data from a panel of immunohistochemical markers. The scores range from 0 to 100, and categorized as: no response: 0-30, weak response: 31-55, moderate response: 56-80, and strong response: 81- 100. In the calibration tests, concentration A demonstrated a strong response, concentrations B demonstrated a weak response, and concentrations C-E showed no response. Working concentration B was thus elected for further studies. The weak response shown by that concentration is suitable for interaction testing by allowing a large enough margin for demonstrating synergy if exists with the other materials tested (i.e., mushroom composition, taxol).

[0082] A calibration experiment for the mushroom composition was then conducted, testing the two formulations of the mushroom composition listed in Table 5.

Table 5. The formulation of the mushroom compositions tested

[0083] According to the score, formulation 1 demonstrated a moderate response and formulation 2 demonstrated a strong response. Based on the results we suspected that DMSO may interfere with the activity of components in the extract and formulation 2 was thus elected for further studies. Furthermore, in a combination testing, each of the combined substances when tested alone should give a weak response such that a strong response is only observed when all tested items are combined. As such, based on the strong response observed for the tested concentration of formulation 2, a decision to proceed to the main experiment with a 1:2 dilution of the tested concentration was taken.

[0084] For the main experiment, samples are evaluated according to the following protocol:

1. Cancer samples are brought to the Curesponse laboratory within 6 hours of harvest in preservation medium. Upon arrival in the laboratory, background details and images of the sample are documented. A DNA sample is frozen for later analysis.

2. Tissue is sectioned into multiwell 12 well cResponse plates and cultured in Curesponse’ s proprietary culture medium (Day 0). 3. The following day (Day 1), drugs are added according to the following (in duplicates).

Table 6. Experimental design - cResponse Ex Vivo Organ Culture System

* Taxol is used at a low concentration, which indicates a range of lOpM to 40pM such that very sensitive tissues may demonstrate a response to that concentration of Taxol, but the majority will not.

4. Culture medium are collected on day 1 (pre-treatment) and day 3 (post-treatment) and frozen at -20C for multiplex ELISA analysis of cytokine secretion (TNF-a, Interferon gamma, IL2, IL4, IL6, IL8, IL10, Granzyme B, , TGFb, VEGF).

5. Drugs are refreshed and the tumor sections are cultured for an additional 48 hours (to Day 5) and then fixed in 4% formalin and processed into parrafin blocks.

6. Slides with 4 pM sections are prepared for histopathological evaluation.

7. Slides are stained with H&E and evaluated.

[0085] Analysis is done based on the validated procedures (https://www.curesponse.com/resources/research-and-evidence/). Based on the results of the preliminary studies conducted, an enhanced effect of the combination of the cannabinoid composition and the mushroom composition compared to that of each one of the compositions alone is expected; and an enhanced effect of the cannabinoid composition when applied together with taxol is expected, demonstrating a synergistic effect between said composition and said chemotherapeutic drug as shown above in vitro. Moreover, the combined expected to be effect achieved by the combination of the compositions is expected to be further enhanced when applying said combination together with taxol, demonstrating a synergistic effect between said combination and said chemotherapeutic drug, as shown above in vitro. The combination of the two compositions, when applied together with taxol, is expected to show more founded synergistic effect, and display enhanced cell death and modulation of the immune microenvironment. REFERENCES

Alves P., Amaral C., Teixeira N., Correia-da-Silva, G. Cannabis sativa: Much more beyond A⁹-tetrahydrocannabinol. Pharmacological research, 2020, 157, 104822

Anavi-Goffer S., Baillie G., Irving A. J., Gertsch J., Greig I.R., Pertwee R.G., Ross R.A. Modulation of L-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. Journal of biological chemistry, 2012, 287, 91-104

Blasco-Benito S., Seijo-Vila M., Caro-Villalobos M., Tundidor I., Andradas C., Garcfa-Taboada E., Wade J., Smith S., Guzman M., Perez-Gomez E., Gordon, M. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical Pharmacology, 2018, 157, 285-293

Blasco-Benito S., Moreno E., Seijo-Vila M., Tundidor I., Andradas C., Caffarel M.M., Caro-Villalobos M., Urigiien L., Diez-Alarcia R., Moreno-Bueno G., Hernandez L. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences, 2019, 116, 3863-3872

Caffarel M.M., Sarrio D., Palacios J., Guzman M., Sanchez C. A⁹- tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer research, 2006, 66, 6615-6621.

Caffarel M.M., Andradas C., Mira E., Perez-Gomez E., Cerutti C., Moreno-Bueno G., Flores J.M., Garcia-Real I., Palacios J., Manes S. Guzman M. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular cancer, 2010, 9, 1-11

Chang S.T., Wasser S.P. Current and future research trends in agricultural and biomedical applications of medicinal mushrooms and mushroom products. International journal of medicinal mushrooms, 2018, 20

Cohen N., Cohen J., Asatiani M.D., Varshney V.K., Yu H.T., Yang Y.C., Li Y.H., Mau J.L. Wasser S.P. Chemical composition and nutritional and medicinal value of fruit bodies and submerged cultured mycelia of culinary -medicinal higher Basidiomycetes mushrooms. International journal of medicinal mushrooms, 2014, 16

De Petrocellis L., Ligresti A., Schiano Moriello A., lappelli M., Verde R., Stott C.G., Cristino L., Orlando P., Di Marzo V. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms, Br. J. Pharmacol. 2013, 168, 79-102 Formato M., Crescente G., Scognamiglio M., Fiorentino A., Pecoraro M.T., Piccolella S., Catauro M., Pacifico S. (-)-Cannabidiolic acid, a still overlooked bioactive compound: An introductory review and preliminary research. Molecules, 2020, 25, 2638

Gavert N., Zwang Y., Weiser R., Greenberg O., Halperin S., Jacobi O., Mallei G., Sandler O., Berger A.J., Stossel E., Rotin D., Grinshpun A., Kamer I., Bar J., Pines G., Saidian D., Bar I., Golan S., Rosenbaum E., Nadu A., Ben-Ami E., Weitzen R., Nechushtan H., Golan T., Brenner B., Nissan A., Margalit O., Hershkovitz D., Lahat G., Straussman R. Ex vivo organotypic cultures for synergistic therapy prioritization identify patient- specific responses to combined MEK and Src inhibition in colorectal cancer. Nat Cancer, 2022, 3, 219-231

Kosgodage U.S., Mould R., Henley A.B., Nunn A.V., Guy G.W., Thomas E.L., Inal J.M., Bell J.D., Lange S. Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. Front. Pharmacol., 2018, 9, 889

Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1375-1387

McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., Desprez P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular cancer therapeutics, 2007, 6, 2921-2927

McKallip R.J., Nagarkatti M., Nagarkatti P.S. A9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005, 174, 3281-3289

Murphy E.J., Masterson C., Rezoagli E.„ O'Toole D.„ Major I., Stack G.D., Lynch M., Laffey J.G., Rowan N.J. p-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects-- Implications for coronavirus disease (COVID-19) immunotherapies. Science of the Total Environment, 2020, 732, 139330

Murase R., Kawamura R., Singer E., Pakdel A., Sarma P., Judkins J., Elwakeel E., Dayal S., Martinez-Martinez E., Amere M., Gujjar R. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. British journal of pharmacology, 2014, 171, 4464-4477 Nabissi, M., Morelli, M.B., Santoni, M. and Santoni, G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis, 2013, 34, 48-57

Salpeter S., Bar V., Aharon S., Torovsky L., Zundelevich A., Shachar H., Shapira H., Gavert N., Straussman R., Golan S., Rosenbaum E., Golan T., Berger R., Dotan Z., Leibovici D., Breuer S., Rotenberg Y., Zick A., Hubert A., Nechushtan H., Neev G. A clinical trial of cResponse, a functional assay for cancer precision medicine. Proceedings of the 112^th Annual Meeting of the American Association for Cancer Research, 2021 April 10-15. Philadelphia (PA): AACR; 2021. Abstract nr CT209

Seltzer E.S., Watters A.K., MacKenzie D., Granat L.M., Zhang, D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers, 2020, 12, 3203

Shrivastava A., Kuzont. os. i PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-tal. between apoptosis and autophagy. Mol Cancer Ther, 2011, 10, 1161-1172

Sultan A.S., Marie M.A., Sheweita S.A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. The Breast, 2018, 41, 34-41

Taha T., Meiri D., Talhamy S., Wollner M., Peer A. Bar-Sela, G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist, 2019, 24, 549-554

Takeda S., Okajima S., Miyoshi H., Yoshida K., Okamoto Y., Okada T., Amamoto T., Watanabe K., Omiecinski C.J., Aramaki H. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology letters, 2012, 214, 314-319

Takeda S., Yoshida K., Nishimura H., Harada M., Okajima S., Miyoshi H., Okamoto Y., Amamoto T., Watanabe K., Omiecinski C.J., Aramaki H. A⁹- Tetrahydrocannabinol disrupts estrogen- signaling through up-regulation of estrogen receptor P (ERP). Chemical research in toxicology, 2013, 26, 1073-1079

Takeda S., Himeno T., Kakizoe K., Okazaki H., Okada T., Watanabe K., Aramaki H. Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness. Journal of natural medicines, 2017, 71, 286-291

Vetvicka V., Vannucci L., Sima P. Richter J. Beta glucan: supplement or drug? From laboratory to clinical trials. Molecules, 2019, 24, 1251 Wasser S.P. Medicinal mushrooms in human clinical studies. Part I. Anticancer, oncoimmunological, and immunomodulatory activities: a review. International Journal of Medicinal Mushrooms, 2018, 19

Wasser S.P. Medicinal mushroom science: history, current status, future trends, and unsolved problems. International journal of medicinal mushrooms, 2010, 12

Xue Z., Ma Q., Chen Y., Lu Y., Wang Y., Jia Y., Zhang M., Chen H. Structure characterization of soluble dietary fiber fractions from mushroom Lentinula edodes (Berk.) Pegler and the effects on fermentation and human gut microbiota in vitro. Food Research International, 2020, 129, 108870

Zhelyazkova M., Kirilov B., Momekov, G. The pharmacological basis for application of cannabidiol in cancer chemotherapy. Pharmacia, 2020, 4, 239-253

Zhou X.L., Guo X., Song Y.P., Zhu C.Y., Zou W. The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling. Acta Pharmacologica Sinica, 2018, 39, 459-471

Claims

1. A method for treatment of a breast cancer in an individual in need thereof, said individual undergoing a conventional therapy for treating said breast cancer, and said method comprising administering to said individual, as an adjunctive therapy, a cannabinoid composition, mushroom composition, or combination thereof, wherein:

(i) said cannabinoid composition comprises cannabidiol (CBD) or an enantiomer, diastereomer, or mixture thereof, A⁹-tetrahydrocannabinol (A⁹-THC) or an enantiomer, diastereomer, or mixture thereof, cannabidivarin (CBDV) or an enantiomer, diastereomer, or mixture thereof, cannabidiolic acid (CBDA) or an enantiomer, diastereomer, or mixture thereof, and optionally one or more terpenes; and

(ii) said mushroom composition comprises Agaricus bisporus extract, Ganoderma lucidum extract, Ganoderma lucidum spore extract, Grifola frondosa extract, Lentinus edodes extract, and Trametes versicolor extract.

2. The method of claim 1, wherein said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about32% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of from about 3% to about 23% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of from about 33% to about 53% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids.

3. The method of claim 2, wherein said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of about 13% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of about 43% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids.

4. The method of any one of claims 1-3, wherein said cannabinoid composition comprises one or more terpenes constituting up to about 3% by weight of said cannabinoid composition.

5. The method of claim 4, wherein said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene.

6. The method of claim 5, wherein said one or more terpenes comprises linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, preferably at about equal amounts.

7. The method of claim 1, wherein said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25% by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3% by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24% by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33% by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29% by weight of total extracts.

8. The method of claim 7, wherein said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

9. The method of claim 1, wherein:

(i) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of from about 3% to about 23% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of from about 33% to about 53% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids; and

(ii) said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25% by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3% by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24% by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33% by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29% by weight of total extracts.

10. The method of claim 9, wherein:

(i) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of about 13% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of about 43% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; and

(ii) said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

11. The method of claim 9 or 10, wherein said cannabinoid composition comprises one or more terpenes constituting up to about 3% by weight of said cannabinoid composition.

12. The method of claim 11, wherein said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene.

13. The method of claim 12, wherein said one or more terpenes comprises linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, preferably at about equal amounts, constituting from about 1% to about 2% by weight of said cannabinoid composition.

14. The method of claim 1, wherein said cannabinoid composition is in the form of a nutraceutical or pharmaceutical composition; and/or said mushroom composition is in the form of a nutraceutical composition.

15. The method of claim 1, wherein each one of said compositions is independently formulated for oral or oral mucosal (e.g., sub- or supra-lingual, or buccal) administration, or for inhalation.

16. The method of claim 15, wherein each one of said compositions is independently formulated as a liquid dosage form such as a solution, emulsion, syrup, and elixir; or as a solid dosage form such as a tablet, capsule, and pill.

17. The method of any one of claims 1-16, comprising administering to said individual a combination of said cannabinoid composition and said mushroom composition.

18. The method of claim 17, wherein said cannabinoid composition and said mushroom composition are administered concomitantly, or sequentially at any order.

19. The method of claim 17, wherein said cannabinoid composition and said mushroom composition are formulated as a sole composition.

20. The method of any one of claims 1-19, wherein said breast cancer is luminal A breast cancer, luminal B breast cancer, human epidermal growth factor receptor 2 (HER2)- positive breast cancer, or triple-negative breast cancer.

21. The method of any one of claims 1-20, wherein said conventional therapy is a chemotherapy, hormonotherapy, immunotherapy, tyrosine kinase inhibitor-based therapy, antiangiogenic based-therapy, antibody-based therapy, or a combination thereof.

22. The method of claim 21, wherein said chemotherapy comprises administration of a taxane such as paclitaxel, albumin paclitaxel, and docetaxel; a nonsteroidal aromatase inhibitor such as anastrozole, letrozole, and tamoxifen; or an anthracycline such as doxorubicin, liposomal doxorubicin, and epirubicin.

23. A cannabinoid composition, mushroom composition, or a combination thereof, for use as an adjunctive therapy to a conventional therapy in the treatment of a breast cancer, wherein:

24. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 23, wherein said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of from about 3% to about 23% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of from about 33% to about 53% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids.

25. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 24, wherein said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of about 13% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of about 43% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids.

26. The cannabinoid composition, mushroom composition, or combination thereof, for use according to any one of claims 23-25, wherein said cannabinoid composition comprises one or more terpenes constituting up to about 3% by weight of said cannabinoid composition.

27. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 26, wherein said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene.

28. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 27, wherein said one or more terpenes comprises linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, preferably at about equal amounts.

29. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 23, wherein said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25% by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3% by weight of total extracts, a Grifola frondosa extract in an amount of from about 4% to about 24% by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33% by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29% by weight of total extracts.

30. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 29, wherein said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

31. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 23, wherein:

(iii) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of from about 3% to about 23% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of from about 33% to about 53% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of from about 12% to about 32% by weight of total cannabinoids; and

(iv) said mushroom composition comprises an Agaricus bisporus extract in an amount of from about 5% to about 25% by weight of total extracts, a Ganoderma lucidum extract in an amount of from about 18% to about 38% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of from about 1% to about 3% by weight of total extracts, a Grifola f rondo sa extract in an amount of from about 4% to about 24% by weight of total extracts, a Lentinus edodes extract in an amount of from about 13% to about 33% by weight of total extracts, and a Trametes versicolor extract in an amount of from about 9% to about 29% by weight of total extracts.

32. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 31, wherein:

(iii) said cannabinoid composition comprises CBD or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; A⁹-THC or an enantiomer, diastereomer, or mixture thereof in an amount of about 13% by weight of total cannabinoids; CBDV or an enantiomer, diastereomer, or mixture thereof in an amount of about 43% by weight of total cannabinoids; and CBDA or an enantiomer, diastereomer, or mixture thereof in an amount of about 22% by weight of total cannabinoids; and

(iv) said mushroom composition comprises an Agaricus bisporus extract in an amount of about 15% by weight of total extracts, a Ganoderma lucidum extract in an amount of about 28% by weight of total extracts, a Ganoderma lucidum spore extract in an amount of about 2% by weight of total extracts, a Grifola frondosa extract in an amount of about 14% by weight of total extracts, a Lentinus edodes extract in an amount of about 23% by weight of total extracts, and a Trametes versicolor extract in an amount of about 19% by weight of total extracts.

33. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 31 or 32, wherein said cannabinoid composition comprises one or more terpenes constituting up to about 3% by weight of said cannabinoid composition.

34. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 33, wherein said one or more terpenes comprises at least two of linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene.

35. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 34, wherein said one or more terpenes comprises linalool, limonene, a-pinene, P-caryophyllene, and P-myrcene, preferably at about equal amounts, constituting from about 1% to about 2% by weight of said cannabinoid composition.

36. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 23, wherein said cannabinoid composition is in the form of a nutraceutical or pharmaceutical composition; and/or said mushroom composition is in the form of a nutraceutical composition.

37. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 36, wherein each one of said compositions is independently formulated for oral or oral mucosal (e.g., sub- or supra-lingual, or buccal) administration, or for inhalation.

38. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 37, wherein each one of said compositions is independently formulated as a liquid dosage form such as a solution, emulsion, syrup and elixir; or as a solid dosage form such as a tablet, capsule, and pill.

39. The combination of said cannabinoid composition and said mushroom composition, for use according to any one of claims 23-38.

40. The combination of said cannabinoid composition and said mushroom composition for use according to claim 39, wherein said compositions are administered concomitantly, or sequentially at any order.

41. The combination of said cannabinoid composition and said mushroom composition for use according to claim 39, wherein said compositions are formulated as a sole composition.

42. The cannabinoid composition, mushroom composition, or combination thereof, for use according to any one of claims 23-41, wherein said breast cancer is luminal A breast cancer, luminal B breast cancer, human epidermal growth factor receptor 2 (HER2)- positive breast cancer, or triple-negative breast cancer.

43. The cannabinoid composition, mushroom composition, or combination thereof, for use according to any one of claims 23-42, wherein said conventional therapy is a chemotherapy, hormonotherapy, immunotherapy, tyrosine kinase inhibitor-based therapy, antiangiogenic based-therapy, antibody-based therapy, or a combination thereof.

44. The cannabinoid composition, mushroom composition, or combination thereof, for use according to claim 43, wherein said chemotherapy comprises administration of a taxane such as paclitaxel, albumin paclitaxel, and docetaxel; a nonsteroidal aromatase inhibitor such as anastrozole, letrozole, and tamoxifen; or an anthracycline such as doxorubicin, liposomal doxorubicin, and epirubicin.

45. A kit comprising a cannabinoid composition, a mushroom composition, and optionally instructions to administer said compositions, as a combined treatment, for providing an adjunctive therapy to an individual having a breast cancer and undergoing a conventional treatment for treating said breast cancer, wherein: